Dianthus Therapeutics: Myasthenia Gravis Drug Shows Promise
Dianthus's Claseprubart shows promising Phase 2 results for gMG, significantly improving daily activities & muscle strength with good safety. Plans for a convenient self-administered dose and a Phase 3 trial in 2026.
This post is for paying subscribers only
Already have an account? Sign in.